摘要
Abstract
Objective To discuss the clinical efficacy of human recombinant endostatin combined with pemetrexed in treating middle-late stage non-small cell lung cancer.Methods 68 cases of patients with locally advanced non-small cell lung cancer were randomly divided into control group and observation group,34 cases in each group.Two groups of patients were given pemetrexed chemotherapy,based on this,the observation group was give human recombinant endostatin,3 weeks for 1 course of treatment,two groups of patients were treated for 2 courses.In the process of treatment,corresponding support treatment according to the patient re-sponse was given.Results After treatment,the recent curative effect of observation group was 67.64%,which was higher than 50.00% of control group(P <0.05).KPS score after treatment,two groups of patients was decreased,the drop degree of the observa-tion group was less than the control group,but the group differences were statistically significant(P <0.05);1 month after completion of treatment,two groups of patients′KPS score was increased,the improvement in the observation group was better than that of control group,the differences were statistically significant(P <0.05 ).After treatment,the observation group of patients in the progress of time,the median survival and a year survival rates were significantly higher than that of control group,the differences were statistically significant(P <0.05 ).The total incidence rate of adverse reactions were similar between the two groups and had no statistical differ-ence(P >0.05).Conclusion The recombinant human endostatin combined with pemetrexed in treating locally advanced non-small cell lung cancer in the near future curative effect is good,can significantly improve the quality of survival,tumor in the progress of time,the median survival and a year survival rate,and on the basis of combination treatment does not significantly increase the inci-dence of adverse reactions,which is worthy of clinical promotion.关键词
重组人血管内皮抑制素/培美曲塞/非小细胞肺癌/临床疗效Key words
recombinant human endostatin/pemetrexed/non-small-cell lung cancer/clinical efficacy分类
医药卫生
